• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    23Andme Holding Co. (NQ: ME )

    0.3390 +0.0049 (+1.47%)
    Streaming Delayed Price Updated: 10:00 AM EDT, Aug 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 129,867
    Open 0.3331
    Bid (Size) 0.3347 (4)
    Ask (Size) 0.3390 (2)
    Prev. Close 0.3341
    Today's Range 0.3330 - 0.3390
    52wk Range 0.3020 - 1.250
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025
    ME stock results show that 23andMe Holding beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
    Via InvestorPlace
    23andMe Reports First Quarter Fiscal 2025 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -62.68%
    -62.68%
    1 Month
    -22.92%
    -22.92%
    3 Month
    -37.68%
    -37.68%
    6 Month
    -47.23%
    -47.23%
    1 Year
    -69.18%
    -69.18%

    More News

    Read More
    ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
    Via InvestorPlace
    23andMe Special Committee responds to CEO’s take-private proposal
    From 23andMe, Inc.
    Via GlobeNewswire
    Looking Into 23andMe Holding's Recent Short Interest
    Via Benzinga
    23andMe Announces CEO’s Take-Private Proposal
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe to Report Q1 FY2025 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
    From 23andMe, Inc.
    Via GlobeNewswire
    The 3 Best Personalized Nutrition Stocks to Buy Now
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
    From Kahn Swick & Foti, LLC
    Via Business Wire
    3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
    Via InvestorPlace
    23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
    From 23andMe, Inc.
    Via GlobeNewswire
    3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
    Via The Motley Fool
    3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
    Via InvestorPlace
    23andMe Launches New Genetic Report on Bipolar Disorder
    From 23andMe, Inc.
    Via GlobeNewswire
    Why 23andMe Stock Tumbled 10% on Tuesday
    Via The Motley Fool
    23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
    From 23andMe, Inc.
    Via GlobeNewswire
    Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
    From 23andMe, Inc.
    Via GlobeNewswire
    ME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe to Report Q4 and Full Year FY2024 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case
    From Potter Handy LLP
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.